Boston Scientific aims for top spot in stent market
This article was originally published in Clinica
Executive Summary
"We lead in almost every market in which we participate. The only market where we don't is coronary stenting, where we are the number two player. We are not happy about that." Boston Scientific's CFO Larry Best told the recent Chase Hambrecht & Quist Healthcare conference in San Francisco that the company planned to move into first place. "Our goal is to be number one in stents. We are today a 25%-28% player in stents. No-one should think that Boston Scientific is happy with that," he said.